47 completed, 43 recruiting, 24 terminated, 20 active not recruiting. 81 Phase 2, 57 Phase 1, 11 Phase 3, 3 Not applicable, 2 Early Phase 1.
Follow Marginal Zone Lymphoma: new trials by email Literature Review of Marginal Zone Lymphoma trials Research Report on Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-12-16 | 2026-09-29 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia | Not yet recruiting | Tina Baykaner | 500 | 2026-08-01 | 2026-07-17 | |
| Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Pomalidomide - Indolent Lymphoma, Follicular Lymphoma | Not yet recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-05-01 | 2026-05-27 | |
| Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma lisocabtagene maraleucel - Marginal Zone Lymphoma | Active not recruiting | Bristol-Myers Squibb | 300 | 2026-03-24 | 2026-08-20 | |
| Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Venetoclax, Rituximab - Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 33 | 2026-02-11 | 2026-03-13 |
| Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL Orelabrutinib - Marginal Zone Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2026-01-05 | 2026-03-02 |
| Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma Zanubrutinib, Rituximab - Marginal Zone Lymphoma | Recruiting | Henan Cancer Hospital | 30 | 2025-11-18 | 2025-11-18 | |
| Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Epcoritamab - Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Recruiting | Izidore Lossos, MD | 25 | 2025-10-13 | 2026-10-15 |
| Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas Pemigatinib - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | University of Utah | 1 | 2025-10-03 | 2026-07-09 |
| HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL Tafasitamab, Rituximab, Lenalidomide - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 65 | 2025-08-07 | 2026-08-12 |
| A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas Radiation (Standard), Radiation (Very low dose) - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 375 | 2025-06-09 | 2026-02-17 |
| Combating Cancer-Related Fatigue: A Personalized Supportive Care Program Exercise, Diet - Indolent Lymphomas, Lymphoma | Not applicable | Recruiting | UNC Lineberger Comprehensive Cancer Center | 40 | 2025-06-03 | 2026-07-01 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-08-06 |
| 64Cu-LLP2A for Imaging Hematologic Malignancies 64Cu-LLP2A, PET/CT - Multiple Myeloma, Low-Grade Lymphoma | Early Phase 1 | Terminated | Washington University School of Medicine | 21 | 2025-03-20 | 2026-10-16 |
| Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) Pirtobrutinib, Rituximab - Marginal Zone Lymphoma | Phase 2 | Recruiting | University of Utah | 23 | 2025-02-20 | 2025-12-04 |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies Pirtobrutinib, LV20.19 CAR T cells - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2025-02-06 | 2026-08-06 |
| Epco, Zanu, Ritux for R/R FL or MZL Zanubrutinib, Rituximab, Epcoritamab - Follicular Lymphoma, Lymphoma | Phase 2 | Recruiting | Reid Merryman, MD | 71 | 2025-01-21 | 2026-09-25 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
Showing 20 of 148. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (148) · Lymphoma, Follicular (98) · Lymphoma, Mantle-Cell (68) · Leukemia, Lymphocytic, Chronic, B-Cell (67) · Lymphoma, Large B-Cell, Diffuse (46) · Lymphoma, Non-Hodgkin (43) · Waldenstrom Macroglobulinemia (31) · Lymphoma (26) · Lymphoma, B-Cell (26) · Burkitt Lymphoma (15) · Recurrence (12) · Myelodysplastic Syndromes (10) · Leukemia, Myeloid, Acute (8) · Leukemia (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7)
Hemic and Lymphatic Diseases (148) · Immune System Diseases (147) · Lymphatic Diseases (147) · Neoplasms by Histologic Type (147) · Immunoproliferative Disorders (146) · Lymphoproliferative Disorders (144) · Neoplasms (141) · Lymphoma (122) · Lymphoma, B-Cell (122) · Lymphoma, Non-Hodgkin (105) · Hematologic Diseases (74) · Pathologic Processes (74) · Pathological Conditions, Signs and Symptoms (74) · Disease Attributes (73) · Chronic Disease (68)
Rituximab (36) · Cyclophosphamide (17) · obinutuzumab (15) · Lenalidomide (12) · zanubrutinib (10) · Bendamustine Hydrochloride (9) · Prednisone (9) · fludarabine (9) · ibrutinib (7) · venetoclax (7) · orelabrutinib (5) · ublituximab (5) · CT-P10 (4) · Doxorubicin (4) · Vincristine (4)
Gilead Sciences (5) · TG Therapeutics, Inc. (5) · BeiGene (4) · Memorial Sloan Kettering Cancer Center (4) · University of Miami (4) · University of Washington (4) · BeOne Medicines (3) · City of Hope Medical Center (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · International Extranodal Lymphoma Study Group (IELSG) (3) · Massachusetts General Hospital (3) · Ruijin Hospital (3) · Adicet Therapeutics (2) · Christian Buske (2) · Emory University (2)
United States (106) · China (22) · France (22) · Italy (17) · Australia (16) · United Kingdom (14) · Germany (13) · South Korea (12) · Spain (11) · Poland (9) · Belgium (8) · Switzerland (8) · Austria (7) · Canada (7) · Japan (7)
Ajay K. Gopal (2) · Catherine Thieblemont, MD (2) · Christian Buske, MD (2) · Emanuele Zucca, MD (2) · Izidore Lossos, MD (2) · Nirav Shah, MD (2) · Reid Merryman, MD (2) · Ronald Levy (2) · Adam J Olszewski, MD (1) · Alexey V Danilov (1)
PMID 40550489, PMID 34398557, PMID 34780125, PMID 17242396, PMID 24450858, PMID 25016003, PMID 25145344, PMID 25439689, PMID 26248505, PMID 26913560, PMID 27879257, PMID 28167659, PMID 28945884, PMID 29908231, PMID 30184451, PMID 30811293, PMID 31792945, PMID 32223334, PMID 32582591, PMID 32856068, PMID 33227125, PMID 33297794, PMID 33407745, PMID 33516721, PMID 33676628, PMID 33683917, PMID 34156440, PMID 34187401, PMID 34196037, PMID 34515338, PMID 35135810, PMID 35136603, PMID 35332334, PMID 35460929, PMID 35538512, PMID 35595730, PMID 35597752, PMID 35847727, PMID 35947804, PMID 36385536, PMID 36400069, PMID 36810799, PMID 37192437, PMID 37407001, PMID 37624619, PMID 37682792, PMID 37930156, PMID 37939259, PMID 38319241, PMID 38502198
2018 (4), 2017 (2), 2019 (2), 2023 (2), P30CA033572 (2), R35CA197353 (2), 2014 (1), 2016 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA138292 (1), R01CA214890 (1), R42CA257797 (1), U10CA098543 (1)